Rebecca Karp Leaf, Jodi V. Mones, Tushar Shenoy, Mohamed Warsame, Marina Beltrami Moreira, Sandhya Panch, Andrew D. Leavitt, Rebecca L. Zon, Ellen K. Kendall, Sahar Shahamatdar, Tristan Lim, Can Cui, Debbie Jiang, Sarah Allison Kaunfer, Lavanya Durai, Steven T. Hoge, Julie‐Alexia Dias, Carrie Sha, Aaron Holmes, Neil Easton, Elizabeth M. Corley, Ethan Zhao, Xingyi Li, Amy Spelman, Christina Briggs Amos, Doris Soebbing, Maria Shabih, Trevor Jamison, Bolun Liu, Guleid Hussein, Sumeet K. Yadav, Mohamed I. Elsaid, Dwight H. Owen, Alexa Meara, Patrick K. Juras, Arvind Suresh, Marina Heskel, Jennifer J. Huang, Ilya Glezerman, Ronald S. Go, Kerry L. Reynolds, Hanny Al‐Samkari, Michael H. Kroll, David E. Leaf
ABSTRACT: Immune checkpoint inhibitor-associated immune thrombocytopenia (ICI-ITP) has been described in case reports and small case series, but comprehensive data on its incidence, risk factors, clinical features, treatment, and outcomes are lacking. We reviewed medical records of all adults initiating ICI therapy between 2016 and 2023 at 29 US hospitals across 7 major cancer centers to identify patients with ICI-ITP. Multivariable logistic regression was used to identify risk factors, and Cox modeling was performed to assess the association between ICI-ITP, its severity, and mortality. Among 86 467 patients, ICI-ITP occurred in 214 (0.25%). Independent risk factors included lower baseline platelet count, combination ICI therapy, stage IV cancer, and additional immune-related adverse events. ICI-ITP occurred at a median of 8 weeks (interquartile range [IQR], 4-18) after ICI initiation, with a median nadir platelet count of 41 × 109/L (IQR, 17 × 109/L to 64 × 109/L). Patients were treated with glucocorticoids (n = 106 [49.5%]), immune globulin (n = 39 [18.2%]), and thrombopoietin receptor agonists (n = 29 [13.6%]). Recovery occurred in 161 patients (75.2%) at a median of 2.3 weeks (IQR, 1.0-5.3). Of 76 patients rechallenged with ICIs, 23 (30.3%) developed recurrent ICI-ITP. ICI-ITP and its severity were associated with higher all-cause mortality, with a nearly threefold increase in risk among patients with severe ICI-ITP than those without ICI-ITP (adjusted hazard ratio, 2.96 [95% confidence interval, 2.14-4.08]). These findings establish ICI-ITP as a rare but clinically significant complication of ICI therapy, provide, to our knowledge, the first large-scale description of its risk factors and clinical course, and underscore the importance of timely recognition and management.